Ponezumab

From WikiMD.org
Jump to navigation Jump to search

Ponezumab

Ponezumab (pronounced poh-nez-uh-mab) is a monoclonal antibody designed for the treatment of Alzheimer's disease. It is developed by Pfizer, a multinational pharmaceutical company.

Etymology

The name "Ponezumab" is derived from the standard nomenclature for monoclonal antibodies. The suffix "-mab" is used for all these antibodies, while "Ponezu-" is a unique prefix chosen by the manufacturer.

Function

Ponezumab works by binding to amyloid beta, a protein that forms plaques in the brains of Alzheimer's patients. By binding to this protein, Ponezumab helps to prevent the formation of these plaques, potentially slowing the progression of the disease.

Clinical Trials

Ponezumab has undergone several clinical trials to test its efficacy and safety. In Phase II trials, it was found to be safe and well-tolerated, but did not show significant effects on cognitive function. Further trials are ongoing to determine its potential benefits and risks.

Related Terms

  • Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
  • Amyloid beta: A protein that is thought to play a role in Alzheimer's disease.
  • Clinical trial: A research study that tests how well new medical approaches work in people.

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski